Tempus AI Shares Up After FDA Clearance for In Vitro Diagnostic Device
By Freddy Sebastian
Tempus AI Inc. shares rose after it said it received 510(k) clearance from the Food and Drug Administration for its RNA-based in vitro diagnostic device.
Its stock recently rose 5.2% to $92.85 in morning trading.
RNA sequencing captures a large array of biological information and offers deeper insights into the mechanisms of diseases, including enhanced fusion detection, the healthcare technology company said Monday. RNA analysis is increasingly an important tool in research and development because it can identify molecular pathways and networks that are directly involved in disease progression.
"We have long known that RNA sequencing offers additional insights beyond DNA alone, but only now are we beginning to unlock its full value in supporting therapeutic development," said Kate Sasser, chief scientific officer. "This FDA clearance further demonstrates the promise of RNA sequencing and opens up new opportunities for us with our biopharma customers."
The company said its life science partners would be able to leverage its RNA assay to more precisely identify which patients would be most likely to respond to specific therapies and will be able to design more efficient clinical trials.
Write to Freddy Sebastian at freddy.sebastian@wsj.com
(END) Dow Jones Newswires
September 22, 2025 10:19 ET (14:19 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States